Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction

Daniel J. Sassoon,1 Johnathan D. Tune,1 Kieren J. Mather,2 Jillian N. Noblet,1 Mackenzie A. Eagleson,1 Abass M. Conteh,1 Joshua T. Sturek,1 and Adam G. Goodwill1

Diabetes 2017;66:2230–2240 | https://doi.org/10.2337/db16-1206

This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardiac contractile function at rest and in response to adrenergic stimulation in obese swine after myocardial infarction. Obese Ossabaw swine were subjected to gradually developing regional coronary occlusion using an ameroid occluder placed around the left anterior descending coronary artery. Animals received subcutaneous injections of saline or liraglutide (0.005–0.015 mg/kg/day) for 30 days after ameroid placement. Cardiac performance was assessed at rest and in response to sympathomimetic challenge (dobutamine 0.3–10 µg/kg/min) using a left ventricular pressure/volume catheter. Liraglutide increased diastolic relaxation (dP/dt; Tau1/2; T a u1/e)d u r i n g dobutamine stimulation (P < 0.01) despite having no influence on the magnitude of myocardial infarction. The slope of the end-systolic pressure volume relationship (i.e., contractility) increased with dobutamine after liraglutide (P < 0.001) but not saline administration (P = 0.63). Liraglutide enhanced the slope of the relationship between cardiac power and pressure volume area (i.e., cardiac efficiency) with dobutamine (P = 0.017). Hearts from animals treated with liraglutide demonstrated decreased β1-adrenoreceptor expression. These data support that GLP-1 agonism augments cardiac efficiency via attenuation of maladaptive sympathetic signaling in the setting of obesity and myocardial infarction.

Use of glucagon like peptide 1 (GLP-1)–based therapies for the treatment of type 2 diabetes (T2DM) has increased significantly since their discovery in the 1980s (1). Although these agents demonstrate unequivocal efficacy in the control of blood glucose concentration, an emerging body of evidence indicates direct cardiovascular benefit, including improvements in cardiac contractile function (2), reductions in myocardial infarct size (3) in animal studies, and improved cardiovascular event rates in some but not all clinical trials (4–6). Thus, there is strong interest in these apparent cardioprotective effects of GLP-1–based therapies in clinical applications of obesity and T2DM (7,8).

Prior studies of the cardiovascular effects of GLP-1 have largely been performed in animal models lacking obesity/meteabolic disease phenotypes, in contrast to the fact that most patient populations treated with agents from this therapeutic class are overweight or obese (9). Studies from our laboratory and others have demonstrated obesity-related impairment in cardiovascular effects of GLP-1 agonists, including attenuation of GLP-1–mediated increases in myocardial glucose uptake in obese swine (10) and humans with T2DM (10,11). Further evidence of different responses in obesity comes from our recent report that the GLP-1R agonist exendin-4 augmented end-diastolic volume (EDV) and systolic pressure generation during coronary reperfusion in lean swine while maintaining systolic pressure despite marked reduction in diastolic filling in obese swine (12).

The mechanisms responsible for these obesity-related differences are unknown. However, the capacity for GLP-1 to induce changes in cardiac inotropy (13) and lusitropy (12) implicate underlying differences in adrenergic responsiveness that are known to exist in obesity (14). Such metabolic state–dependent effects of GLP-1 combined with the inconsistent cardiovascular benefits of GLP-1–based therapeutics in clinical trials of patients with diabetes (4,5)
support the need for a better understanding of the cardiac effects of GLP-1 in the setting of obesity and metabolic dysregulation, especially in the setting of complex ischemic heart disease.

This study investigated the potential for liraglutide to influence cardiac function at rest and in response to β-adrenergic receptor (βADR) stimulation in an obese swine model of subacute, progressive coronary artery occlusion. We hypothesized that chronic (~3–4 weeks) liraglutide administration (a GLP-1 analog) would demonstrate cardioprotective capacity in ischemic hearts of obese animals through infarct mitigation and/or alterations in cardiac contractile function.

RESEARCH DESIGN AND METHODS

Surgical Preparation and Experimental Protocol

All experiments involving animals were approved by an Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publica- tion No. 85-23, Revised 2011). Ossabaw swine were fed an obesogenic diet (10,15) for 6 months, after which an ameroid constrictor (Research Instruments Southwest) was placed around the left anterior descending coronary artery (LAD). Next, animals were randomly assigned to saline or liraglutide treatment groups. During the subsequent 4 weeks, liraglutide-treated animals received a step-up protocol of liraglutide (week 1: 0.005, week 2: 0.010, weeks 3 and 4: 0.015 mg/kg/day, delivered subcutaneously once daily), and saline-treated animals received volume-matched saline injections.

After this 4-week treatment period, during which time the ameroid constrictor induced a subacute, unrelieved LAD occlusion, a terminal invivo study was performed. We hypothesized that chronic (~3–4 weeks) liraglutide administration (a GLP-1 analog) would demonstrate cardioprotective capacity in ischemic hearts of obese animals through infarct mitigation and/or alterations in cardiac contractile function.

Infarct Quantification

Immediately subsequent to the physiologic measurements, hearts were fibrillated, excised, and flushed with 4°C, Ca2+-free Krebs buffer via aortic cannulation. Hearts were frozen at −20°C, sliced into 1-cm-thick sections, stained with 1% weight/volume tetrazolium solution, and transferred to a 10% buffered formalin solution for at least 24 h. Formalin-fixed tissues were imaged, and the infarct area (unstained) versus viable tissue (stained) was quantified on each heart slice from each animal by two separate investigators blinded to condition using ImageJ software (National Institutes of Health).

Immunohistochemistry

Endocardial biopsy specimens from the 1-cm-thick heart slices were taken from both the ischemic and normally perfused regions of left ventricular myocardium for histologic analysis. Tissues were processed into 4- to 5-μm-thick slices stained for βADR (PA5-28808; Thermo Fisher, Rockford, IL) and imaged on the Aperio Scan Scope CS whole-slide digital imaging system (Aperio Technologies, Vista, CA) at original magnification ×20. Positive staining was quantified using a positive pixel algorithm (Aperio Technologies), image quantitation software approved by the U.S. Food and Drug Administration for providing molecular imaging analyses in support of new drug applications.

Statistical Analyses

Data are presented as mean ± SEM and were analyzed using SigmaPlot 12 software (Systat Software Inc., San Jose, CA) and SPSS 21 software (IBM). Comparisons were considered statistically significant when \( P < 0.05 \). Treatment groups and ischemic/nonischemic zone results were compared using unpaired t tests or linear mixed modeling evaluating the dobutamine dose response as a repeated measure, as appropriate. For significant ANOVAs, Student-Newman-Keuls post hoc testing was performed to identify pairwise differences between groups. Multiple linear regression and ANCOVA were used to compare the slopes and intercepts of the relationships between cardiac output (CO) versus EDV and cardiac power versus pressure volume (PV) area (PVA).

RESULTS

Phenotypic Characteristics of Obese Swine

Body weight on the day of ameroid placement was not different in animals subsequently assigned to receive saline versus liraglutide (\( P = 0.31 \)) (Table 1). On randomized treatment, the liraglutide-treated animals failed to gain weight, resulting in significantly lower weight at the time of physiologic studies relative to saline controls (\( P = 0.02 \)) (Table 1). Liraglutide therapy did not significantly alter total cardiac mass (\( P = 0.85 \)) (Table 1), heart weight-to-body ratio (\( P = 0.09 \)) (Table 1), or the overall magnitude of infarction (\( P = 0.81 \)) (Fig. 1). Also, left ventricular free wall thickness, measured 2 cm distal to the ameroid location, was not different between treatment groups (saline, 2.3 ± 0.1 vs. liraglutide, 2.3 ± 0.1 cm; \( P = 0.97 \)).

Effects of Liraglutide on Baseline Hemodynamic and Cardiac Parameters

All physiologic data were obtained during an anesthetized procedure at the end of the treatment protocol (Table 2) for cross-sectional comparisons of saline versus liraglutide.

<table>
<thead>
<tr>
<th>Table 1—Phenotype characteristics of obese swine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saline</strong></td>
</tr>
<tr>
<td>Body mass (kg)</td>
</tr>
<tr>
<td>At ameroid placement</td>
</tr>
<tr>
<td>ΔBody weight (kg)</td>
</tr>
<tr>
<td>Heart weight (g)</td>
</tr>
<tr>
<td>Heart weight-to-body weight ratio</td>
</tr>
</tbody>
</table>

Values are mean ± SE for saline (n = 5) and liraglutide (n = 7).
treatment in the setting of subacute unrelied infarction. Mean arterial pressure was similar under resting conditions (P = 0.87), but heart rate was ~40% higher in liraglutide-versus saline-treated animals (Table 2). Heart rate changes (described below) occurred independent of changes to peripheral vascular resistance, which is calculated as mean arterial pressure/CO (saline, 0.03 ± 0.004 vs. liraglutide, 0.03 ± 0.005 mmHg/mL; P = 0.82). Key indices of cardiac function, including ejection fraction, Tau1/2, end-diastolic PV relationship (Table 2), end-systolic elastance (Ees) (Fig. 2D), and CO (Fig. 3B) were unaffected by liraglutide administration under resting conditions.

Effects of Liraglutide Treatment on Responses to Adrenergic Stimulation
Systemic arterial pressures were not significantly increased by dobutamine (0.3–10 μg/kg/min) and were unaffected by liraglutide treatment (Table 2). Dobutamine increased heart rate in both groups, with an enhanced effect in liraglutide-treated animals (P = 0.001) (Table 2) and reduced CO (~35%; P = 0.02) in liraglutide-treated animals at the highest levels of dobutamine (Fig. 3B). Liraglutide treatment was also associated with enhanced diastolic function, as indicated by increases in −dP/dt min and Tau (Table 2), consistent with the enhanced CO of liraglutide-treated animals (P = 0.04) (Fig. 3B). End-diastolic PV relationships were unaffected by liraglutide treatment (Table 2).

Representative PV loops shown in Fig. 2A and B illustrate dobutamine-mediated reductions in EDV (right side of the PV loop), and end-systolic volume (ESV; left side of the PV loop), which decreased to a similar magnitude in both groups (EDV, P = 0.19; ESV, P = 0.47). Stroke volume decreased similarly in both groups (P = 0.48), reaching significance at the 10 μg/kg/min dose (saline, P = 0.005; liraglutide, P = 0.02). Overall, the volume axis intercept (V0; greatest left ventricular volume at which pressure is zero) was lower in liraglutide-treated swine (P < 0.001) (Fig. 2C). Load-dependent measures of cardiac contraction were enhanced by dobutamine in both groups, with dose-dependent increases in dP/dt max (P = 0.001) as well as significant reductions of contraction time in the liraglutide groups (Table 2). Accordingly, the mean relaxation was different between groups across the range of the dobutamine challenge (dP/dt min, P < 0.001; Tau −1/2, P = 0.06; Tau −1/τ, P = 0.005). The slope of end-systolic PV relationship, a load-independent measure of cardiac contractility (Ees), was not different on average between groups (P = 0.38) (Fig. 2D); however, dobutamine infusion significantly increased contractility at the 10 μg/kg/min dose in liraglutide- but not saline-treated animals (P < 0.001) (Fig. 2D).

Effect of Liraglutide and Adrenergic Stimulation on Cardiac Function and Efficiency
EDV was significantly decreased relative to baseline in both saline- and liraglutide-treated animals at the highest concentrations of dobutamine (P < 0.001 for each group) (Fig. 3A). Dobutamine-dependent reductions in EDV were also similar between treatment groups (P = 0.11) (Fig. 3A). Dobutamine-driven changes in CO were dose-dependently decreased in liraglutide-treated animals, achieving significance at the highest dose (P = 0.02) (Fig. 3B). In saline-treated animals, which demonstrated modestly lower baseline CO values, CO was not significantly changed by dobutamine administration (Fig. 3B) despite significant increases in heart rate (Table 2).

PVA is linearly related to left ventricular myocardial oxygen consumption (MV O2) (16) and was not different between treatment groups under resting conditions (P = 0.29) or across the range of dobutamine exposures (P = 0.43) (Fig. 3C). However, PVA was decreased compared with resting baseline in liraglutide-treated animals at 3.0 (P = 0.005) and 10 μg/kg/min (P < 0.001) dobutamine doses; there were no significant changes in PVA from baseline within the saline-treated animals (Fig. 3C).

Cardiac power (product of stroke volume, mean aortic pressure, and heart rate) was significantly increased under resting conditions by liraglutide treatment (P = 0.03) and was greater in those animals across the range of dobutamine administration (P = 0.04) (Fig. 3D). Dobutamine administration resulted in significant reductions in cardiac power at the 3 μg/kg/min (P = 0.03) and 10 μg/kg/min (P = 0.01) doses in liraglutide-treated animals (Fig. 3D).
### Table 2

- **Effects of liraglutide therapies on hemodynamic and cardiac parameters**

<table>
<thead>
<tr>
<th></th>
<th>Liraglutide</th>
<th>Dobutamine</th>
<th>Lir*Dob</th>
<th>Dobutamine</th>
<th>Interaction</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Systolic pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>93 ± 6</td>
<td>79 ± 6</td>
<td>99 ± 6</td>
<td>8 ± 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>94 ± 3</td>
<td>93 ± 4</td>
<td>99 ± 4</td>
<td>4 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diastolic pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>64 ± 5</td>
<td>56 ± 5</td>
<td>66 ± 5</td>
<td>6 ± 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>65 ± 4</td>
<td>36 ± 4</td>
<td>36 ± 4</td>
<td>4 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mean pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>77 ± 7</td>
<td>67 ± 7</td>
<td>78 ± 7</td>
<td>7 ± 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>78 ± 7</td>
<td>37 ± 4</td>
<td>37 ± 4</td>
<td>4 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heart rate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>77 ± 13</td>
<td>80 ± 14</td>
<td>107 ± 14</td>
<td>14 ± 15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>107 ± 9</td>
<td>91 ± 2</td>
<td>91 ± 2</td>
<td>4 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ejection fraction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>48 ± 9</td>
<td>10 ± 3</td>
<td>82 ± 8</td>
<td>8 ± 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>40 ± 5</td>
<td>53 ± 8</td>
<td>53 ± 8</td>
<td>8 ± 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contraction time</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>53 ± 2</td>
<td>44 ± 3</td>
<td>44 ± 3</td>
<td>3 ± 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>63 ± 7</td>
<td>76 ± 0</td>
<td>76 ± 0</td>
<td>0 ± 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Relaxation time</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>142 ± 16</td>
<td>131 ± 13</td>
<td>131 ± 13</td>
<td>13 ± 13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>120 ± 16</td>
<td>117 ± 10</td>
<td>117 ± 10</td>
<td>10 ± 10</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>dPmax (mmHg/s)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>1,204 ± 157</td>
<td>1,230 ± 170</td>
<td>1,548 ± 250</td>
<td>2,350 ± 364*</td>
<td>0.618†, 0.001</td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>1,536 ± 108</td>
<td>1,460 ± 101</td>
<td>1,584 ± 208</td>
<td>2,249 ± 392*</td>
<td>0.798*</td>
<td></td>
</tr>
<tr>
<td><strong>dPmin (mmHg/s)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>2,858 ± 66</td>
<td>2,832 ± 68</td>
<td>2,955 ± 123</td>
<td>1,126 ± 235</td>
<td>0.001, 0.412</td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>2,115 ± 108</td>
<td>2,182 ± 102</td>
<td>2,182 ± 123</td>
<td>1,541 ± 229*</td>
<td>0.014, 0.798</td>
<td></td>
</tr>
<tr>
<td><strong>Tau 1/2 (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>32 ± 22</td>
<td>33 ± 23</td>
<td>43 ± 33</td>
<td>0 ± 42</td>
<td>0.006, 0.002</td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>29 ± 22</td>
<td>11 ± 11</td>
<td>12 ± 12</td>
<td>1 ± 17</td>
<td>0.05, 0.17</td>
<td></td>
</tr>
<tr>
<td><strong>Tau1/e (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>22 ± 22</td>
<td>22 ± 22</td>
<td>32 ± 32</td>
<td>6 ± 31</td>
<td>0.004, 0.002</td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>21 ± 21</td>
<td>9 ± 9</td>
<td>11 ± 11</td>
<td>1 ± 11</td>
<td>0.05, 0.11</td>
<td></td>
</tr>
<tr>
<td><strong>End-diastolic PV relationship</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>0.24 ± 0.10</td>
<td>0.22 ± 0.12</td>
<td>0.28 ± 0.12</td>
<td>0.08 ± 0.22</td>
<td>0.283, 0.726</td>
<td></td>
</tr>
<tr>
<td>Liraglutide</td>
<td>0.17 ± 0.05</td>
<td>0.10 ± 0.12</td>
<td>0.12 ± 0.12</td>
<td>0.10 ± 0.36</td>
<td>0.36, 0.12</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SE for saline (n = 5) and liraglutide (n = 7). Treatment column reports P values for differences in mean response across dobutamine administration. *P > 0.05 vs. baseline value. **P > 0.05 vs. baseline value. †P > 0.05 vs. baseline value. ‡P > 0.05 vs. baseline value.
Saline-treated animals, which showed lower cardiac power overall, demonstrated no change in cardiac power in response to dobutamine administration at any dose. Figure 4 presents the relationship between CO and EDV for the saline- and liraglutide-treated animals before and during dobutamine administration. Liraglutide increased the slope of the relationship between CO and EDV with dobutamine challenge \( P = 0.002 \), resulting in greater CO at higher values of EDV. When cardiac power is expressed relative to PVA, it produces an index of cardiac work efficiency – power per unit of oxygen consumed (16,17). Therefore, to assess whether liraglutide altered cardiac work efficiency, we plotted cardiac power relative to PVA (Fig. 5A). This relationship demonstrates that liraglutide treatment increased power generation at higher MvO\(_2\) \( (P = 0.001) \) for slope of relationship saline vs. liraglutide by multiple linear regression; that is, cardiac efficiency was greater in liraglutide-treated animals. Figure 5B demonstrates that cardiac efficiency (ratio of cardiac power to PVA) was enhanced by liraglutide and that dobutamine challenge resulted in significant enhancement of efficiency in liraglutide- but not saline-treated animals.

**DISCUSSION**

GLP-1 receptor activation produces potentially cardioprotective phenomena in healthy animal models receiving recombinant GLP-1–based therapies (1–3,10,13,18). Inconsistent data exist regarding the cardioprotective potential of these therapies in the setting of ischemic heart disease with underlying obesity and metabolism dysfunction (4–6). Because GLP-1–based therapies are classically used for the purpose of glucose regulation in T2DM, a population with significant lifetime cardiovascular risk, understanding the cardiovascular effects of GLP-1–based treatments in the setting of obesity is crucial.

Here we examined the effects of GLP-1 receptor activation via liraglutide on cardiac function at rest and in response to sympathetic stimulation in an obese swine model of slowly developing myocardial ischemia. We hypothesized that chronic \( \geq 3 \)–4 weeks) administration of the GLP-1 analog liraglutide would demonstrate cardioprotective capacity in ischemic hearts of obese animals through infarct mitigation and/or alterations in cardiac contractile function. This study identifies the capacity of liraglutide to improve cardiac performance of significantly infarcted hearts in an energetically favorable fashion and is the first to identify a relationship between myocardial \( \beta_1 \)ADR abundance and GLP-1–based therapies.

**Infarct Size**

This study examined GLP-1–based cardioprotection in the context of a slowly developing, unrelieved, regional myocardial

![Figure 2](image-url)
infarction using an ameroid constrictor around the LAD. Ameroid constrictors are a well-established tool in the study of coronary artery disease in swine models (19,20). Post-mortem analyses verified a 100% closure rate of the ameroid constrictors in all study animals; that is, each animal experienced total loss of flow to the LAD perfusion territory distal to the ameroid constrictor. The consistency of closure between animals and treatment groups is evident in the tetrazolium staining, which demonstrated a consistent; 15% infarction of the left ventricle (Fig. 1). This point is critical because these data demonstrate that differences in cardiac function with liraglutide administration are not related to underlying differences in the magnitude of infarction.

Data regarding the capacity of GLP-1 therapeutics to mitigate myocardial infarction remain equivocal because similar studies in swine from Kristensen et al. (21) and Ekström et al. (22) failed to show infarct mitigation, whereas Timmers et al. (3) and others have demonstrated infarct reductions with GLP-1–based therapies. Similarly equivocal findings exist in rodent models as well, which show varied capacity for infarct mitigation (23,24). Some discrepancy in the findings of the animal studies from different laboratories could arise as a result of differences in the duration of ischemic insult and the presence or absence of a reperfusion window. We posit that liraglutide failed to mitigate infarct size in the current study because of the absence of reperfusion (i.e., chronic total coronary artery occlusion) and because of the limited endogenous collateral network in swine (25). These factors would limit or prevent exposure of ischemic tissues to receive the therapeutic agent and have important implications for the cardioprotective efficacy in the clinical circumstance of chronically developing coronary occlusion because clinical studies also report varied efficacy of GLP-1 therapies to mitigate infarct (26–29).

Hemodynamics
Pressor effects of GLP-1 are particularly pronounced in rodent models, which routinely show significant increases in mean pressure as high as 20 mmHg (13), inconsistent with human studies that report elevations of 2–3 mmHg or reductions of <3 mmHg in response to GLP-1 receptor agonism (8,13,14). The hemodynamic profile of liraglutide-treated animals in this study is consistent with work by Lovshin et al. (30), who found that 3 weeks of liraglutide treatment failed to modulate blood pressure in patients with T2DM. The absence of a significant pressor response in this study (Table 2) is therefore consistent with the body of literature in human subjects that demonstrates variable or modest effects of GLP-1 drugs on blood pressure (13).

Central effects of GLP-1 therapies to modulate hemodynamics are well established in rodents but remain equivocal in large-animal models and humans (13). Previous work by our group identified no effect of hexamethonium treatment on changes to cardiac performance resulting from acute administration of GLP-1 (7-36) in the setting of
myocardial ischemia (2). These data further support an absence of sympathomimetic modulation by GLP-1–based therapies with regard to pressor responses because systolic, diastolic, and mean pressures are all consistent between treatment groups across the range of dobutamine concentrations. Similarly, GLP-1–mediated chronotropy (positive or negative) is highly variable and differs by species (13). Tachycardia appears to be most pronounced in species that demonstrate the greatest pressor responses to GLP-1 therapies (13), whereas meta-analyses of human studies report only modest GLP-1–related tachycardia (1).

In response to the sympathomimetic challenge, GLP-1 therapy resulted in a significantly higher heart rate across the dose response range ($P = 0.001$) (Table 1), although the magnitude of change relative to baseline was consistent between groups ($P = 0.44$). These data support a potential to modulate heart rate, but whether this is the result of nodal activity remains to be determined. To assess the potential of liraglutide to produce peripheral dilation, peripheral vascular resistance was calculated and not different between groups ($P = 0.82$), removing the potential of peripheral dilation to bias the result.

**Cardiac Function**

Liraglutide significantly lowered $V_0$, an index of end-diastolic relaxation, both at baseline and at lower dobutamine concentrations. This decrease runs counter to previously documented effects of GLP-1 (7–36) administration in the setting of acute myocardial ischemia (2), where preload-dependent increases in CO were accomplished in a GLP-1–dependent fashion, reflected by a constant $Ees$ and increased $V_0$. However, prior observations were made in lean swine, whereas the current observations included only obese swine. The current findings are consistent with recent observations that demonstrated GLP-1 analog–dependent increases in inotropy of obese hearts in the setting of ischemia-reperfusion (12). These changes in $V_0$ could reflect low levels of positive inotropy before overt increases in $Ees$ or could be the result of significant and differential cardiac remodeling between the two treatment groups (31). Regardless, the contrast of the current data against those obtained in lean animals support the paradigm that metabolic status significantly affects the cardiac effects of GLP-1 therapies.

Contractility, as determined by $Ees$, was not enhanced with dobutamine challenge in saline-treated animals when examined as an absolute change or as a change relative to
baseline. By contrast, liraglutide therapies preserved the ability of infarcted hearts to respond to adrenoreceptor activation in that there was a continuous increase in Ees across the range of dobutamine concentrations both absolute and relative to baseline. Examination of the relationship between EDV and CO (Frank-Starling curve) (Fig. 4) reveals that liraglutide treatment results in a shift of the relationship of EDV to CO such that CO increases as EDV increases in liraglutide-treated animals relative to their saline counterparts. Classically, this relationship has been used to establish whether a system is demonstrating an inotropic response. We therefore interpret this set of observations as further evidence for a modest positive inotropic effect of liraglutide in the setting of significant myocardial infarction.

**Cardiac Efficiency**

Pioneering work by Suga (32,33) demonstrated a linear relationship between PVA and MvO2. Therefore, the data obtained with transient inferior vena cava occlusion in this study enabled us to use PVA as an index of MvO2. This index of oxygen consumption was similar between groups at baseline (P = 0.29). Despite similar PVAs, cardiac power (work per unit time; estimated here as the triple product of stroke volume, mean aortic pressure, and heart rate) was significantly greater at baseline in liraglutide-treated animals (Fig. 3D) at rest (P = 0.03) and over the range of dobutamine administration (P = 0.04). The relationship between cardiac power (work) and PVA (MvO2) is an index of cardiac efficiency (Fig. 5). Owing to enhanced power without attendant increases in MvO2, liraglutide treatment resulted in a significant enhancement of cardiac efficiency under conditions of enhanced metabolic demand imposed by dobutamine.

Obesity and ischemia-related heart failure are associated with reduced cardiac function and with impaired work efficiency (34,35), making therapies that simultaneously improve function and efficiency an attractive prospect. Our observations suggest that liraglutide may provide this advantageous combination of effects. The mechanism(s) underlying the improved work efficiency is of some interest. It is well recognized that utilization of fatty acids as a fuel source in the heart is accompanied by some ATP consumption unrelated to contractility through effects including an unfavorable phosphate-to-oxygen ratio, mitochondrial uncoupling, and futile cycling of metabolic intermediates (36). By corollary, switching away from fatty acid utilization can allow improved efficiency. Previous studies of GLP-1 agonists in animal models and in humans have described shifts in myocardial fuel selection toward glucose (11,37), with the important caveat that obesity and T2DM appear to induce resistance to these fuel-selection effects of GLP-1 agonists including in the swine model used in the current studies (10). The effects we observed were specific to the circumstance of acutely increased work under β-adrenergic stimulation. However, the response to acute increases in myocardial work under β-adrenergic stimulation is to preferentially utilize fatty acids, including mobilizing fatty acid stores from adipose tissue (36). The effect we observed prevailed despite these effects. Effects of GLP-1 on handling of metabolic intermediates, such as pyruvate (38) or effects to modulate mitochondrial handling of fuels or mitochondrial ATP production could help explain the observed effects but such phenomena have not been directly evaluated to
date. Further study of GLP-1 effects on myocardial substrate selection and ATP generation, evaluating the effects of treatment type, duration, and metabolic status as modulators of these effects is needed.

β1ADR Expression
In light of the different β-adrenergic responsiveness induced by liraglutide treatment, we evaluated β1ADR expression in the myocardium (Fig. 6). Unexpectedly, and in contrast to the observed enhancements of adrenergic responsiveness relative to saline-treated animals, the normally perfused myocardium of liraglutide-treated animals exhibited ~50% lower levels of β1ADR. This raises the possibility that liraglutide is affecting function and efficiency via effects on adrenergic responsiveness. It is well recognized that β1ADR antagonism can improve function in chronic heart failure (39) and that via effects to reduce fatty acid oxidation, β1ADR activation can improve work efficiency as well (40). Specific evaluations of effects on β-adrenergic responsiveness, and the role of adrenergic signaling as a modulator of GLP-1 agonist effects on contractility and work efficiency will help clarify the effect of the observed changes in receptor density.

Although the increased cardiac function in liraglutide-treated swine despite lower expression of β1ADR may seem paradoxical, this phenotypic combination has been previously observed as conferring benefit in other clinically relevant scenarios (41–43). Reduction in β1ADR signaling, via β-blockade, is frequently used to improve cardiac function, including in the setting of heart failure (44). Reducing β1ADR signaling disrupts the positive feedback loop (maladaptive adrenergic signaling) that pushes the heart toward hypertrophy and eventually failure (45) while also enhancing efficiency via decreased myocardial fat oxidation (40). Other ways that GLP-1 agonism might be influencing cardiac mechanical work without additional demand for myocardial oxygen uptake include effects on calcium handling (as seen, for example, with digoxin or milrinone) or effects on the contractile machinery (46). Prior proteomic studies performed by our laboratory (12) found that exendin-4, another GLP-1 agonist, changed the expression of key calcium-handling proteins, components and regulators of sarcomeric proteins, and protein mediators of intermediary metabolism.

Some efforts to explore the signaling mechanism supporting effects of GLP-1 on myocardial function have been undertaken. Noyan-Ashraf et al. (47) recently demonstrated significant enhancement to cardiac function with liraglutide therapies in obese mice that could be abolished through the application of an AMPK inhibitor. We previously found enhanced P38–mitogen-activated protein kinase activity in response to direct application of GLP-1 (7–36) to porcine myocardial slices (10). These pathways represent targets of further investigations to better understand the cardioprotective and hemodynamic effects of GLP-1–related therapies. Among other considerations is the question whether effects are exerted via direct effects on the canonical receptor, effects on a noncanonical receptor, or secondary effects resulting from effects in peripheral tissue. Our finding that responsiveness to adrenergic stimulation is preserved with liraglutide and that efficiency is improved in the treatment arm provides new opportunity for potentially translational applications of GLP-1–based therapies.

Limitations
Molecular analysis after euthanasia was limited by the need for intact, uncompromised heart slices for accurate infarct measurement. Formalin fixation and staining with tetrazolium chloride prevented subsequent use of these tissues for gel-based analysis or ELISA. Biopsy samples from formalin-fixed tissues were used for immunohistochemistry. To minimize bias inherent to histologic analysis, we used digital pathology techniques to quantify stain. Liraglutide treatment was associated with decreased weight gain across the study, introducing modest differences in obesity at the time of the study. Although our power to demonstrate small effects was limited by the relatively small numbers of animals in the study, these samples were sufficient to identify large important effects on key outcome variables.

Conclusions and Implications
This study is the first to identify the potential for GLP-1–based therapies to modulate myocardial β1ADR abundance and, by extension, the potential for liraglutide therapies to improve cardiac performance of significantly infarcted hearts in an energetically favorable fashion via attenuation of maladaptive β1ADR signaling, similar to β-blockade therapies used to combat chronic heart failure. These findings could explain recent observations by Marso et al. (6), who found that the rate of fatal cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke was lower in liraglutide-treated patients with T2DM than the placebo group. Taken together, these data support that liraglutide (and potentially other GLP-1 agonists) therapies can augment cardiac efficiency and function through alterations to β1ADR expression and sensitivity, independent of changes to infarct area.

Funding. Support was provided by National Heart, Lung, and Blood Institute grant HL-117620 (J.D.T. and K.J.M., primary investigators) and by National Center for Advancing Translational Sciences grant TL1-TR-000162 (A. Shekher, primary investigator).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. D.J.S., J.N.N., M.A.E., A.M.C., and A.G.G. performed studies and reviewed and edited the manuscript. J.D.T. and K.J.M. contributed to discussion and reviewed and edited the manuscript. J.T.S. assisted with data analysis. A.G.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References


37. Grover GJ, Kostis JB, Weiss HR, Li JK, Kovacs T, Kedem J. Effect of beta-adrenoceptor stimulation or blockade on regional myocardial function and regional...
O2 consumption during myocardial ischemia. Arch Int Pharmacodyn Ther 1988;291:68–87
44. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Cir-
culation 2000;101:558–569
46. ter Keurs HE. The interaction of Ca2+ with sarcomeric proteins: role in function and dysfunction of the heart. Am J Physiol Heart Circ Physiol 2012;302:H38–H50